NivolumabColitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2017年 / 1668卷 / 1期

关键词：

D O I：

10.1007/s40278-017-35775-2

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：303 / 303

相关论文

共 50 条

[31] Ipilimumab/nivolumabColitis and skin toxicity: case report
Reactions Weekly, 2018, 1696 (1) : 213 - 213
[32] Ipilimumab/nivolumabColitis and bilateral mydriasis: case report
Reactions Weekly, 2022, 1907 (1) : 266 - 266
[33] Ipilimumab/nivolumabColitis and lack of efficacy: case report
Reactions Weekly, 2022, 1903 (1) : 214 - 214
[34] NivolumabColitis and large-duct cholangiopathy: case report
Reactions Weekly, 2020, 1789 (1) : 193 - 193
[35] Ipilimumab/nivolumabColitis and off label use : case report
Reactions Weekly, 2024, 2018 (1) : 252 - 252
[36] Binimetinib/encorafenib/ipilimumab/nivolumabColitis and diarrhoea: case report
Reactions Weekly, 2023, 1959 (1) : 147 - 147
[37] Ipilimumab/nivolumabColitis, diarrhoea and skin rash: case report
Reactions Weekly, 2019, 1739 (1) : 158 - 158
[38] Infliximab/ipilimumab/nivolumabColitis and lack of efficacy: case report
Reactions Weekly, 2021, 1836 (1) : 419 - 419
[39] Ipilimumab/nivolumabColitis, hepatitis and acute renal injury: case report
Reactions Weekly, 2024, 2026 (1) : 161 - 161
[40] Ipilimumab/nivolumabColitis, hyperthyroidism and type 1 diabetes mellitus: case report
Reactions Weekly, 2018, 1705 (1) : 174 - 174

← 1 2 3 4 5 →